Mubadala Investment Co PJSC Sells Its Shareholding in Lockheed Martin Corp, According to SEC Filing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 hours ago
0mins
Should l Buy PFE?
Source: moomoo
Investment Dissolution: Mubadala Investment Company has dissolved its share stake in Lockheed Martin Corporation.
SEC Filing: The dissolution was officially reported through a filing with the Securities and Exchange Commission (SEC).
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 27.580
Low
24.00
Averages
28.56
High
35.00
Current: 27.580
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer's BRAFTOVI Regimen Shows Significant Improvement in Colorectal Cancer Outcomes
- Clinical Trial Results: Pfizer's BRAFTOVI regimen demonstrated a statistically significant improvement in progression-free survival (PFS) for patients with specific mutations in metastatic colorectal cancer during the BREAKWATER trial, indicating its superior efficacy over traditional treatments.
- Efficacy Comparison: The BREAKWATER trial revealed a confirmed objective response rate (ORR) of 60.9% for BRAFTOVI, significantly higher than the 40.0% observed in patients receiving chemotherapy with or without bevacizumab, showcasing its potential in clinical applications.
- Market Performance Analysis: Pfizer's stock is currently priced at $27.75, trading 3.5% below its 20-day simple moving average, indicating short-term weakness, despite a 7.90% increase over the past 12 months.
- Analyst Ratings: The stock carries an average price target of $29.67, with analysts maintaining a neutral rating; adjustments from Cantor Fitzgerald and UBS reflect a cautious outlook on its future performance.
See More
Pfizer Reports Positive BREAKWATER Trial Results for BRAFTOVI
- Trial Results: Pfizer's BREAKWATER trial shows that the combination of BRAFTOVI with cetuximab and FOLFIRI significantly improves progression-free survival (PFS) in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), indicating a potential shift in treatment practices.
- Survival Rate Improvement: The overall survival (OS) also demonstrated clinically meaningful prolongation, further validating the efficacy of BRAFTOVI and potentially offering a new treatment option for previously untreated BRAF V600E-mutant mCRC patients, addressing a significant unmet need.
- Safety Profile: At the time of the PFS analysis, the safety profile of BRAFTOVI was consistent with known components, with no new safety signals identified, suggesting a favorable safety profile that enhances its clinical applicability.
- FDA Submission Plans: Pfizer plans to submit detailed results to the FDA to support the potential approval of BRAFTOVI in combination with cetuximab and FOLFIRI for BRAF V600E-mutant mCRC patients, further advancing the drug's market prospects.
See More
Mubadala Investment Co PJSC Reduces ARM Holdings PLC Share Stake by 8.3% to 1.4 Million Sponsored ADS, According to SEC Filing
- Investment Stake Reduction: Mubadala Investment Company has cut its share stake in Arm Holdings by 8.3%, reducing its ownership to 1.4 million shares.
- Sponsored Ads Impact: The reduction in stake is highlighted in a recent SEC filing, indicating potential implications for sponsored ads and investment strategies.
See More
Mubadala Investment Co PJSC Reduces Stake in Adobe Inc by 49.0% to 11,570 Shares, According to SEC Filing
- Investment Stake: Mubadala has cut its share stake in Adobe by 49.0%, reducing its holdings to 11,570 shares.
- Regulatory Filing: The reduction in shares was disclosed in a recent SEC filing.
See More
Mubadala Investment Co PJSC Increases Stake in CVS Health Corp by 17.3% to 149,769 Shares, According to SEC Filing
Investment Increase: Mubadala Investment Company has raised its stake in CVS Health Corporation by 17.3%.
Share Count: The new total of shares held by Mubadala in CVS Health is now 149,769 shares.
See More
Mubadala Investment Co PJSC Increases Shareholding in Gilead Sciences Inc by 30.4% to 100,178 Shares, According to SEC Filing
Investment Increase: Mubadala Investment Company has raised its share stake in ILEAD Sciences by 30.4%.
New Share Count: Following the investment, Mubadala now holds a total of 100,178 shares in ILEAD Sciences.
See More
Pfizer's BRAFTOVI Regimen Shows Significant Improvement in Colorectal Cancer Outcomes
- Clinical Trial Results: Pfizer's BRAFTOVI regimen demonstrated a statistically significant improvement in progression-free survival (PFS) for patients with specific mutations in metastatic colorectal cancer during the BREAKWATER trial, indicating its superior efficacy over traditional treatments.
- Efficacy Comparison: The BREAKWATER trial revealed a confirmed objective response rate (ORR) of 60.9% for BRAFTOVI, significantly higher than the 40.0% observed in patients receiving chemotherapy with or without bevacizumab, showcasing its potential in clinical applications.
- Market Performance Analysis: Pfizer's stock is currently priced at $27.75, trading 3.5% below its 20-day simple moving average, indicating short-term weakness, despite a 7.90% increase over the past 12 months.
- Analyst Ratings: The stock carries an average price target of $29.67, with analysts maintaining a neutral rating; adjustments from Cantor Fitzgerald and UBS reflect a cautious outlook on its future performance.
See More
Pfizer Reports Positive BREAKWATER Trial Results for BRAFTOVI
- Trial Results: Pfizer's BREAKWATER trial shows that the combination of BRAFTOVI with cetuximab and FOLFIRI significantly improves progression-free survival (PFS) in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), indicating a potential shift in treatment practices.
- Survival Rate Improvement: The overall survival (OS) also demonstrated clinically meaningful prolongation, further validating the efficacy of BRAFTOVI and potentially offering a new treatment option for previously untreated BRAF V600E-mutant mCRC patients, addressing a significant unmet need.
- Safety Profile: At the time of the PFS analysis, the safety profile of BRAFTOVI was consistent with known components, with no new safety signals identified, suggesting a favorable safety profile that enhances its clinical applicability.
- FDA Submission Plans: Pfizer plans to submit detailed results to the FDA to support the potential approval of BRAFTOVI in combination with cetuximab and FOLFIRI for BRAF V600E-mutant mCRC patients, further advancing the drug's market prospects.
See More
Mubadala Investment Co PJSC Reduces ARM Holdings PLC Share Stake by 8.3% to 1.4 Million Sponsored ADS, According to SEC Filing
- Investment Stake Reduction: Mubadala Investment Company has cut its share stake in Arm Holdings by 8.3%, reducing its ownership to 1.4 million shares.
- Sponsored Ads Impact: The reduction in stake is highlighted in a recent SEC filing, indicating potential implications for sponsored ads and investment strategies.
See More
Mubadala Investment Co PJSC Reduces Stake in Adobe Inc by 49.0% to 11,570 Shares, According to SEC Filing
- Investment Stake: Mubadala has cut its share stake in Adobe by 49.0%, reducing its holdings to 11,570 shares.
- Regulatory Filing: The reduction in shares was disclosed in a recent SEC filing.
See More
Mubadala Investment Co PJSC Increases Stake in CVS Health Corp by 17.3% to 149,769 Shares, According to SEC Filing
Investment Increase: Mubadala Investment Company has raised its stake in CVS Health Corporation by 17.3%.
Share Count: The new total of shares held by Mubadala in CVS Health is now 149,769 shares.
See More
Mubadala Investment Co PJSC Increases Shareholding in Gilead Sciences Inc by 30.4% to 100,178 Shares, According to SEC Filing
Investment Increase: Mubadala Investment Company has raised its share stake in ILEAD Sciences by 30.4%.
New Share Count: Following the investment, Mubadala now holds a total of 100,178 shares in ILEAD Sciences.
See More
